BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
01 mai 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
25 avr. 2024 09h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
27 mars 2024 16h00 HE
|
BioCardia, Inc.
BioCardia®, Inc. today reported financial results for the year ended December 31, 2023
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
20 mars 2024 07h00 HE
|
BioCardia, Inc.
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 mars 2024 07h00 HE
|
BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
12 mars 2024 07h00 HE
|
BioCardia, Inc.
Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure study
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
04 mars 2024 08h00 HE
|
BioCardia, Inc.
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction...
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
08 févr. 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions...
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
31 janv. 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions...
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
03 janv. 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...